Compositions and methods for increasing energy metabolism
Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.
1. A method for treating obesity in a subject in need thereof comprising administering a composition comprising:
(a) at least about 500 mg of leucine and/or at least about 200 mg of one or more metabolites thereof, wherein the one or more leucine metabolites are selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and beta-hydroxymethylbutyrate (HMB); and
(b) a synergistically effective amount of a phosphodiesterase 5 (PDE 5) inhibitor, wherein the PDE 5 inhibitor comprises sildenafil.
2. The method of claim 1 , wherein the amount of the phosphodiesterase 5 (PDE 5) inhibitor is a sub-therapeutic amount.
3. The method of claim 2 , wherein the composition comprises a sub-therapeutic amount of component (b) that is between 0.1 and 20 mg of sildenafil.
4. The method of claim 1 , wherein the leucine in component (a) is free leucine.
5. The method of claim 1 , wherein the component (a) comprises between 500 to 2000 mg of free leucine.
6. The method of claim 1 , wherein the composition further comprises less than 1% of an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine in free amino acid form.
7. The method of claim 1 , wherein the composition further comprises less than 1% of isoleucine and valine.
8. The method of claim 1 , further comprising administering a pharmaceutically active agent other than the PDE 5 inhibitor and the leucine and/or the leucine metabolite.
9. The method of claim 1 , further comprising administering an anti-diabetic agent.
10. The method of claim 9 , wherein the anti-diabetic agent is administered in a sub-therapeutic amount.
11. The method of claim 9 , wherein the anti-diabetic agent is a biguanide or thiazoladinedione.
12. The method of claim 11 , wherein the biguanide is metformin.
13. The method of claim 12 , wherein the anti-diabetic agent comprises at least 25 mg of metformin.
14. The method of claim 9 , wherein component (b) comprises between 0.1 and 10 mg of sildenafil, component (a) comprises between 500 and 2000 mg of free leucine, and the anti-diabetic agent comprises at least 250 mg of metformin.
15. The method of claim 1 , further comprising administering resveratrol.
16. The method of claim 1 , further comprising an anti-obesity agent.
17. The method of claim 16 , wherein the anti-obesity agent is selected from the group consisting of: lipase inhibitors, dopaminergic compounds, noradrenergic compounds, serotoninergic compounds, cannabinoid receptor antagonists, incretin mimetic, pramlintide, and central nervous system (CNS) agents.
18. The method of claim 1 , wherein the composition is formulated as a unit dosage.
19. The method of claim 1 , wherein the composition is formulated as a tablet, capsule, or food product.
20. The method of claim 1 , wherein treating obesity is characterized by a reduction in body weight, reduction in weight gain, reduction in adipose volume, and/or increase in fat oxidation.
21. The method of claim 1 , wherein the composition is administered to the subject twice a day.
22. The method of claim 1 , wherein the composition is administered to the subject once a day.